UnitedHealth CEO: Unknowns of Biogen Alzheimer’s drug mean insurer won’t yet cover it

(By Nick Moran for Becker’s Hospital Review)

UnitedHealth Group CEO Andrew Witty said the payer needs to see more data on Aduhelm, Biogen’s controversial Alzheimer’s drug, before it will cover it.  Continue reading the article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org